A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours (original) (raw)

Access this article

Log in via an institution

Subscribe and save

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

1. Tang DG, Chen YQ, Honn KV (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93:5241–5246
   Article PubMed CAS Google Scholar
2. Crooks SW, Stockley RA (1998) Leukotriene B4. Int J Biochem Cell Biol 30(2):173–178
   Article PubMed CAS Google Scholar
3. Hagmann W (1997) Lipoxygenase in human tumor cells. Pathol Oncol Res 3(2):83–88
   CAS PubMed Google Scholar
4. Reich R, Martin GR (1996) Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 51(1):1–17
   Article PubMed CAS Google Scholar
5. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B (1996) The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1300(3):240–246
   PubMed Google Scholar
6. Mann EL, Spiro JD, Chen LL, Kreutzer DL (1994) Phospholipid metabolite expression by head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 120(7):763–769
   PubMed CAS Google Scholar
7. Jackson, WT, Froelich LL, Boyd RJ, Schrementi JP, Saussy DL, Schultz RM, Sawyer JS, Sofia MJ, Herron DK, Goodson T, Snyder DW, Pechous PA, Spaethe SM, Roman CR, Fleisch JH (1999) Pharmacologic actions of the second-generation Leukotriene B4 Receptor Antagonist LY293111: in vitro studies. J Pharmacol Exp Ther 288(1):286–294
   PubMed CAS Google Scholar
8. Mommers JM, Van Tossum MM, Kooijmans-Otero ME, Parker FL, van de Kerkhof PC (2000) VML 295(LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. Br J Dermatol 142(2):259–266
   Article PubMed CAS Google Scholar
9. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O’Connor BJ (1996) Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51(12):1178–1173
   Article PubMed CAS Google Scholar
10. Marshall M, Diaz HB, Brozinick J et al (2002) LY293111 inhibits tumor cell growth in vitro through an apparent PPARγ agonist activity. Proc Amer Assoc Cancer Res 43:957 (abstract 4741)
    Google Scholar
11. Vamecq J, Latruffe N (1999) Medical significance of peroxisome proliferator-activated receptors. Lancet 354:141–148
    Article PubMed CAS Google Scholar
12. Koeffler HP (2003) Peroxisome proliferators-activated receptor γ and cancers. Clin Can Res 9:1–9
    CAS Google Scholar
13. Hennig R, Ding X, Tong W, Witt RC, Jovanovic BD, Adrian TE (2004) Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Letters 210:41–46
    Article PubMed CAS Google Scholar
14. Ding X, Talamonti M, Bell R Jr, Adrian TE (2005) A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs 16(5):467–473
    Article PubMed CAS Google Scholar
15. Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff, M, Konopleva M (2005) Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 19:1977–1984
    Article PubMed CAS Google Scholar
16. Tong W-G, Ding X-Z, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE (2002) Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cell. Clin Cancer Res 8:3232–3242
    PubMed CAS Google Scholar
17. Schwartz GK, Weitzman A, O’Reilly E, Brail L, de Alwis DP, Cleverly A, Barile-Thiem B, Vinciguerra V, Budman DR (2005) Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol 23(23):5365–5373
    Article PubMed CAS Google Scholar
18. Rosen LS (1998) Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology suppl 6:103–109
    Google Scholar
19. Budman DR, Calabro A (2004) Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anti-Cancer Drugs 15(9):877–881
    Article PubMed CAS Google Scholar
20. Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M (1996) Rationale for the dosage and schedule of CPT-11(irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 7(8):837–842
    PubMed CAS Google Scholar
21. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 92:205–216
    Article PubMed CAS Google Scholar
22. Abigerges D, Chabot GG, Armand J-P, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210–221.
    PubMed CAS Google Scholar
23. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Albers SA, Schaaf LJ, Elfring G, Miller LL (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6(6):2236–2244
    PubMed CAS Google Scholar

Download references